Impact of body mass index on relapse in children with acute lymphoblastic leukemia treated according to Nordic treatment protocols.
Adolescent
Body Mass Index
Child
Child, Preschool
Clinical Decision-Making
Disease Management
Female
Humans
Kaplan-Meier Estimate
Male
Obesity
/ complications
Overweight
/ complications
Precursor Cell Lymphoblastic Leukemia-Lymphoma
/ complications
Prognosis
Proportional Hazards Models
Recurrence
Registries
Scandinavian and Nordic Countries
/ epidemiology
acute lymphoblastic leukemia
body mass index
children
obesity
survival
Journal
European journal of haematology
ISSN: 1600-0609
Titre abrégé: Eur J Haematol
Pays: England
ID NLM: 8703985
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
10
06
2020
revised:
02
09
2020
accepted:
03
09
2020
pubmed:
11
9
2020
medline:
30
7
2021
entrez:
10
9
2020
Statut:
ppublish
Résumé
High body mass index (BMI) is associated with poorer survival in childhood acute lymphoblastic leukemia (ALL), but the actual impact on the risk of relapse still needs to be clarified. We evaluated the impact of BMI at diagnosis on the risk of relapse in children with ALL treated according to Nordic Society of Paediatric Haematology and Oncology (NOPHO) protocols. In a multicenter study, we collected data on BMI at diagnosis and outcome of 2558 children aged 2.0-17.9 years diagnosed between 1992 and 2016. Patients were divided into four groups according to International Obesity Task Force (IOTF) childhood BMI cut-offs: underweight, <17; healthy weight, 17-25; overweight, 25-30; and obese, ≥30 kg/m In Cox multivariate regression analyses, an increased risk of relapse was observed in children aged 10-17.9 years with unhealthy BMI at diagnosis (underweight hazard ratio HR: 2.90 [95% confidence interval: 1.24-6.78], P = .01; overweight, HR: 1.95 [1.11-3.43], P = .02, and obese HR: 4.32 [95% 2.08-8.97], P < .001), compared to children with healthy weight. BMI had no impact on relapse in children under 10 years of age. High BMI, and especially obesity at diagnosis, is an independent adverse prognostic factor for relapse in older children with ALL.
Identifiants
pubmed: 32909636
doi: 10.1111/ejh.13517
pmc: PMC7693088
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
797-807Subventions
Organisme : Barncancerfonden
ID : TJ2018-0093
Informations de copyright
© 2020 The Authors. European Journal of Haematology published by John Wiley & Sons Ltd.
Références
J Pediatr Hematol Oncol. 2014 Apr;36(3):234-6
pubmed: 24276040
Leuk Lymphoma. 2019 Dec;60(13):3146-3153
pubmed: 31264493
Leukemia. 2010 Feb;24(2):345-54
pubmed: 20010622
Blood. 2014 Dec 18;124(26):3932-8
pubmed: 25349177
Nat Rev Cancer. 2004 Aug;4(8):579-91
pubmed: 15286738
Blood Cancer J. 2017 Feb 17;7(2):e531
pubmed: 28212374
Int J Pediatr Obes. 2010 Dec;5(6):458-60
pubmed: 20233144
Leukemia. 2018 Mar;32(3):606-615
pubmed: 28819280
Bull World Health Organ. 2007 Sep;85(9):660-7
pubmed: 18026621
J Obes. 2018 Nov 1;2018:7048078
pubmed: 30515322
J Pediatr Hematol Oncol. 2013 Mar;35(2):98-102
pubmed: 23242330
J Clin Oncol. 2007 May 20;25(15):2063-9
pubmed: 17513811
Obes Rev. 2003 Nov;4(4):195-200
pubmed: 14649370
Leuk Res. 2013 May;37(5):503-9
pubmed: 23332453
Am J Clin Nutr. 2016 Mar;103(3):808-17
pubmed: 26864366
Eur J Haematol. 2011 Jan;86(1):38-46
pubmed: 21077959
Acta Paediatr Suppl. 2006 Apr;450:76-85
pubmed: 16817681
Haematologica. 2015 Jan;100(1):62-9
pubmed: 25304613
Cancer Res. 2009 Oct 1;69(19):7867-74
pubmed: 19773440
BMJ. 2000 May 6;320(7244):1240-3
pubmed: 10797032
Int J Obes (Lond). 2014 Sep;38 Suppl 2:S99-107
pubmed: 25376223
Leuk Lymphoma. 2012 Sep;53(9):1677-81
pubmed: 22390648
Eur J Clin Nutr. 1990 Jan;44(1):45-60
pubmed: 2354692
Int J Pediatr Obes. 2007;2(1):62-4
pubmed: 17763012
Pediatr Blood Cancer. 2015 Mar;62(3):434-9
pubmed: 25407299
Leukemia. 2000 Dec;14(12):2267-75
pubmed: 11187918
Int J Pediatr Obes. 2011 Oct;6(5-6):325-31
pubmed: 21916784
Cancer. 2018 Nov 1;124(21):4248-4259
pubmed: 30358906
Lancet. 2014 Aug 30;384(9945):766-81
pubmed: 24880830
J Clin Oncol. 2003 Apr 1;21(7):1332-9
pubmed: 12663723
Eur J Haematol. 2020 Dec;105(6):797-807
pubmed: 32909636
J Clin Oncol. 2014 May 1;32(13):1331-7
pubmed: 24687836
Cancer Res. 2013 May 15;73(10):2998-3006
pubmed: 23585457
Br J Haematol. 2014 Apr;165(1):126-33
pubmed: 24428625
Lancet Oncol. 2013 Mar;14(3):199-209
pubmed: 23395119
BMJ. 2007 Jul 28;335(7612):194
pubmed: 17591624
Blood. 2006 Dec 15;108(13):3997-4002
pubmed: 16917005
Eur J Haematol. 2013 May;90(5):404-12
pubmed: 23461707
Leuk Lymphoma. 2016 May;57(5):1140-8
pubmed: 26453440
Pediatr Obes. 2012 Aug;7(4):284-94
pubmed: 22715120
Obesity (Silver Spring). 2011 Sep;19(9):1908-11
pubmed: 21720424